LifeCare Hospitals

LifeCare Hospitals operated a patient-care unit within Memorial Medical Center, and its place in the disaster became inseparable from the questions that followed: whether its patients could have been evacuated, what medication they received, and how responsibility was divided among the hospital, the company, government officials, and individual clinicians. The evidence does not reduce those questions to a single institutional verdict. It records both the distress of LifeCare staff who believed help came too slowly and the forensic and legal disputes over the deaths of patients in its care.

Operations at Memorial

LifeCare’s patients occupied the hospital’s seventh floor, while its pharmacy was also located inside the Memorial complex. The companies’ shared premises brought their operations into direct contact during the emergency, but their patients and records remained identifiable as LifeCare’s. Later, investigators reviewed LifeCare medical charts alongside toxicology findings, making the company’s documentation an important source for reconstructing what happened to particular patients.

The pharmacy became a concrete focus of the investigation. During a search of the shuttered hospital, pharmacist Steven Harris confirmed that 125 ten-milligram vials of morphine were missing from the LifeCare pharmacy, as were dozens of injectable vials of Versed and Ativan. Other controlled drugs remained. The selective absence of those medications was an investigative lead, not by itself proof of who had taken or administered them. The distinction mattered: inventory evidence could establish what was missing, while patient records, witness accounts, and forensic analysis were needed to examine how drugs related to individual deaths.

Patients, Evacuation, and Staff Experience

Gina Isbell, a LifeCare nurse, told investigators that the company had resources that could have been used to bring out both patients and employees. She believed government officials had discouraged LifeCare executives from sending assistance. Her account expressed a continuing sense of abandonment, but it also reflected the limits of what her testimony alone could establish about the decisions made by company leaders or public officials.

Isbell described leaving Memorial in a small boat, exhausted, and then discovering that her home and community in St. Bernard Parish had been lost. She reported poor sleep, nightmares in which she saw patients’ faces, and guilt about the staff she had selected to work during the hurricane as well as the patients who died. Later, she continued to have nightmares and felt permanently changed by the experience. A memory from the helipad offered a counterweight: an eighty-seven-year-old woman told Isbell that she believed she would be alive the next day because of her. Isbell maintained that she and her colleagues had done the best they could and said she would serve in another storm if asked.

Her account places LifeCare’s institutional role alongside the experience of employees who had to live with the consequences. The record gives her view of delayed assistance and her personal aftermath; it does not establish that every LifeCare employee shared one interpretation of the evacuation or its outcome. Her testimony instead shows how the company’s response was remembered by a nurse who had worked amid the crisis and felt responsible both to coworkers and to patients.

Toxicology and Disputed Causes of Death

Forensic testing brought LifeCare patients into a broader investigation of deaths at Memorial. In September, investigators sent tissue samples from eighteen Memorial bodies to National Medical Services, Inc. In an early report on those cases, a laboratory expert said nine tested positive for morphine and about five or six for midazolam. Later, among forty-one bodies from Memorial and LifeCare analyzed by the laboratory, twenty-three tested positive for morphine, midazolam, or both. These results established drug detection in the tested tissues; interpreting what the findings meant for a particular patient’s treatment, timing of death, or cause of death required additional evidence.

The experts cautioned that postmortem tissue results were not equivalent to blood tests from living patients. The bodies had remained in heat before examination, and medical conditions such as kidney or liver disease could affect how drugs accumulated. The experts therefore compared laboratory results with clinical histories and records, asking whether findings could reflect one large dose or repeated administration and whether the timing and medical effects were consistent with the known circumstances of death.

One case illustrates the patient-by-patient approach. Alice Hutzler, a ninety-year-old LifeCare patient being treated for pneumonia, had morphine and midazolam in her liver, brain, and muscle tissue. Her chart, which remained current until a few hours before her death was recorded on September 1, did not show either drug as prescribed. The chart described her as resting comfortably the previous afternoon, and her nurses had not documented pain or distress that night. Hutzler was among nine LifeCare patients found on the seventh floor with one or both drugs in their systems; all nine had been seen alive that morning and were listed as dead that afternoon.

In December, prosecutors sought an expert assessment of four LifeCare patients’ deaths using toxicology reports, medical records, and autopsies. Cyril Wecht concluded that all four had drugs in their bodies that were not prescribed in their records and that the drugs had caused or substantially contributed to their deaths. That assessment represented an expert interpretation of the assembled evidence, not a resolution of every dispute over dosage, intent, or legal responsibility.

Litigation and Institutional Consequences

Families of three of the four LifeCare patients identified in the arrest affidavit, including Emmett Everett and Rose Savoie, filed civil suits against LifeCare and Memorial, as well as Anna Pou, Cheri Landry, and Lori Budo. In two cases, the suits also named Susan Mulderick and LifeCare pharmacist Steven Harris. The complaints alleged euthanasia, inadequate backup power, failed evacuation policies, and abandonment. Everett’s wife, son, and daughter also named Pou’s employer, Louisiana State University. These were allegations in civil litigation, not findings that the defendants had been legally responsible for the deaths.

LifeCare thus appears in the record in several distinct capacities: as the operator of a unit whose patients depended on a wider hospital evacuation; as the employer whose staff later described the crisis and its lasting effects; as the source of pharmacy and medical records examined by investigators; and as a defendant in families’ claims. The evidence connects those institutional dimensions without making them interchangeable. A missing medication inventory, a toxicology result, a witness’s account of delayed help, and a family’s legal allegation each answer a different question. Together, they explain why the company’s operations at Memorial remained central to the investigation, while leaving the ultimate interpretation of individual deaths contested.